Sélectionner une page

Démence

Pour plus d’informations sur les essais cliniques sur l’Alzheimer ou relié à la démence, veuillez contacter Salma Khalil
Chercheur principal: Dr Simon Ducharme
 

Études actuelles en recrutement

Genetic Frontotemporal Dementia Initiative (GENFI)

GENFI investigates both people who have developed symptoms and also people who have a risk of developing symptoms in the future because they carry an abnormal genetic mutation. By studying these individuals who are destined to develop the disease later in life we can understand the development from the very earliest changes. The key objectives of GENFI are therefore to develop markers which help identify the disease at its earliest stage as well as markers that allow the progression of the disease to be tracked.

More information

CHARMED

Prospective Study of Single Subject Cortical Thickness as an Early Diagnostic Biomarker of Frontotemporal Dementia

Intranasal Oxytocin for Frontotemporal Dementia

From clinicaltrials.gov:
The purpose of this study is to assess the safety, tolerability and effects on behaviour of Syntocinon given intranasally (by a spray into the nostrils) compared to placebo (an inactive saline substance that contains no medication) in participants with frontotemporal dementia/Pick’s disease. This study will take place in approximately 15 centres across Canada and the United States. Approximately 112 patients in total will be enrolled in this study. In the first phase we will examine which of three different dosing schedules of oxytocin may be more effective. In the second phase of the study, patients entering the study will be randomized to the oxytocin dosing schedule that appeared most effective in the first phase.

More information

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer’s Disease

From clinicaltrials.gov:
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with Mild Alzheimer’s Disease

More information

Centre de recherche de l’IUGM

Quantitative Magnetic Resonance Imaging of oxygen transport: a new window on mitochondrial dysfunction in Alzheimer’s disease, Phase 3: data acquisition in individuals affected by Alzheimer’s disease and demographically-matched control participants.

More information

A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

From clinicaltrials.gov:
A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

More information

Études actives (ne recrutent pas)

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (ENGAGE)

From clinicaltrials.gov:
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) [ADAS-Cog 13], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) [ADCS-ADL-MCI].

More information